{"id":"im-olanzapine","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Sedation"},{"rate":"10-20","effect":"Weight gain"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"5-10","effect":"Hyperlipidemia"},{"rate":"5-15","effect":"Extrapyramidal symptoms"},{"rate":"5-10","effect":"Injection site reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olanzapine antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, which reduces psychotic symptoms and stabilizes mood. The intramuscular formulation provides rapid onset and improved compliance compared to oral administration, making it suitable for acute agitation or when oral medication is not feasible.","oneSentence":"IM olanzapine is an intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:48:17.012Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute agitation associated with schizophrenia or bipolar disorder"},{"name":"Schizophrenia"},{"name":"Bipolar I disorder"}]},"trialDetails":[{"nctId":"NCT07246187","phase":"PHASE3","title":"Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department","status":"RECRUITING","sponsor":"Mercy Bon Secours Saint Vincent Medical Center","startDate":"2025-11-06","conditions":"Cannabinoid Hyperemesis Syndrome","enrollment":114},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT02380118","phase":"PHASE4","title":"IM Olanzapine Versus Haloperidol or Midazolam","status":"TERMINATED","sponsor":"The University of Hong Kong","startDate":"2014-12","conditions":"Acute Agitation, Behavioural Emergency","enrollment":167},{"nctId":"NCT03899506","phase":"","title":"Olanzapine Versus Midazolam for Agitation","status":"TERMINATED","sponsor":"Hennepin Healthcare Research Institute","startDate":"2018-06-18","conditions":"Agitation,Psychomotor","enrollment":206},{"nctId":"NCT03624322","phase":"PHASE1","title":"Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101","status":"COMPLETED","sponsor":"Impel Pharmaceuticals","startDate":"2018-08-05","conditions":"Acute Agitation","enrollment":38},{"nctId":"NCT03478605","phase":"PHASE2","title":"Trial to Evaluate Efficacy of Olanzapine With Short-acting 5HT3 Inhibitors in Chemotherapy-induced Nausea & Vomiting (CINV) Prophylaxis","status":"UNKNOWN","sponsor":"Blokhin's Russian Cancer Research Center","startDate":"2018-05-25","conditions":"Emesis, Vomiting, Nausea Post Chemotherapy","enrollment":130},{"nctId":"NCT03216941","phase":"PHASE4","title":"Randomised Trial Ketiapine Olanzapine Fast Sedation Agitated Patients Emergency Ward","status":"COMPLETED","sponsor":"Universidad Nacional de Rosario","startDate":"2015-01-01","conditions":"Psychomotor Agitation, Psychiatric Disorder, Emergency Psychiatric","enrollment":500},{"nctId":"NCT00797277","phase":"PHASE3","title":"Intramuscular (IM) Olanzapine Versus IM Haloperidol Plus Lorazepam for Acute Agitation in Schizophrenia","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2006-07","conditions":"Schizophrenia, Schizoaffective Disorder, Agitation","enrollment":67},{"nctId":"NCT01411930","phase":"PHASE4","title":"Acute Impact of Intramuscular (IM) Aripiprazole and Olanzapine on Insulin Resistance in High Risk Prediabetics","status":"COMPLETED","sponsor":"Veterans Medical Research Foundation","startDate":"2009-03","conditions":"Diabetes","enrollment":15},{"nctId":"NCT00970281","phase":"PHASE3","title":"A Study of Olanzapine in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2009-09","conditions":"Schizophrenia","enrollment":91},{"nctId":"NCT00088465","phase":"PHASE3","title":"Open-Label Study of Intramuscular Olanzapine Depot in Patients With Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2004-08","conditions":"Schizophrenic Disorders, Schizoaffective Disorder","enrollment":931},{"nctId":"NCT00640510","phase":"PHASE3","title":"A Study Comparing Rapid Acting Intramuscular Olanzapine and Placebo in Agitated Patients With Schizophrenia","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-03","conditions":"Schizophrenia","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["zyprexa"],"phase":"phase_3","status":"active","brandName":"IM olanzapine","genericName":"IM olanzapine","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IM olanzapine is an intramuscular formulation of olanzapine, an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain. Used for Acute agitation associated with schizophrenia or bipolar disorder, Schizophrenia, Bipolar I disorder.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}